Status:

RECRUITING

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation

Lead Sponsor:

LifeOS Genomics Corporation

Collaborating Sponsors:

National Taiwan University

National Taiwan University Hospital

Conditions:

Non Small Cell Lung Cancer

EGFR T790M

Eligibility:

All Genders

18+ years

Brief Summary

Liquid biopsy plays a pivotal role in cancer therapeutics, encompassing critical applications such as early cancer detection, disease progression monitoring, and tailored treatment plan formulation, h...

Eligibility Criteria

Inclusion

  • aged ≥18 years old.
  • Patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations.

Exclusion

  • Pregnant women.
  • Any condition that, in the opinion of the doctors, may pose a severe risk to the patient or interfere with trial results or participation.

Key Trial Info

Start Date :

September 6 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2028

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06573073

Start Date

September 6 2024

End Date

December 31 2028

Last Update

November 18 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Taiwan University

Taipei, Taiwan, 10617

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation | DecenTrialz